Skip to content

Study Details

Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness

(IRB#: IRB_00151228)

To evaluate the effect of setanaxib on biochemical response at Week 52 in patients with PBC and with elevated liver stiffness and intolerance or inadequate response to UDCA

I AM INTERESTED

  • All genders
  • Over 18 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 18 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Will I be paid for my time?

Yes

For more information contact:

Wendy Fang

wendy.fang@hsc.utah.edu

  801-581-7802

IRB#: IRB_00151228

PI: Shaun Chandna

Department: GASTROENTEROLOGY

Approval Date: 2022-03-23 06:00:00

Specialties: Gastroenterology

Last Updated: 6/8/23